Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CDXS's Cash to Debt is ranked higher than
82% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. CDXS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CDXS' s 10-Year Cash to Debt Range
Min: 2.71  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.52
CDXS's Equity to Asset is ranked lower than
67% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CDXS: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
CDXS' s 10-Year Equity to Asset Range
Min: -1.82  Med: 0.72 Max: 0.79
Current: 0.52
-1.82
0.79
Interest Coverage No Debt
CDXS's Interest Coverage is ranked higher than
66% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CDXS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CDXS' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: -4.79
M-Score: -4.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -52.08
CDXS's Operating margin (%) is ranked higher than
54% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. CDXS: -52.08 )
Ranked among companies with meaningful Operating margin (%) only.
CDXS' s 10-Year Operating margin (%) Range
Min: -155.16  Med: -54.13 Max: -6.65
Current: -52.08
-155.16
-6.65
Net-margin (%) -52.12
CDXS's Net-margin (%) is ranked higher than
53% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. CDXS: -52.12 )
Ranked among companies with meaningful Net-margin (%) only.
CDXS' s 10-Year Net-margin (%) Range
Min: -153.96  Med: -54.01 Max: -7.97
Current: -52.12
-153.96
-7.97
ROE (%) -65.66
CDXS's ROE (%) is ranked lower than
70% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CDXS: -65.66 )
Ranked among companies with meaningful ROE (%) only.
CDXS' s 10-Year ROE (%) Range
Min: -68.88  Med: -45.17 Max: -15.76
Current: -65.66
-68.88
-15.76
ROA (%) -38.76
CDXS's ROA (%) is ranked lower than
61% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. CDXS: -38.76 )
Ranked among companies with meaningful ROA (%) only.
CDXS' s 10-Year ROA (%) Range
Min: -52.02  Med: -30.91 Max: -7.11
Current: -38.76
-52.02
-7.11
ROC (Joel Greenblatt) (%) -378.24
CDXS's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. CDXS: -378.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CDXS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -664.06  Med: -228.54 Max: -35.45
Current: -378.24
-664.06
-35.45
Revenue Growth (3Y)(%) -35.80
CDXS's Revenue Growth (3Y)(%) is ranked lower than
77% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CDXS: -35.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CDXS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -28.85 Max: -35.8
Current: -35.8
EBITDA Growth (3Y)(%) 33.10
CDXS's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. CDXS: 33.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CDXS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 33.1
Current: 33.1
0
33.1
EPS Growth (3Y)(%) 2.80
CDXS's EPS Growth (3Y)(%) is ranked higher than
60% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CDXS: 2.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CDXS' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -26.15 Max: 45.6
Current: 2.8
0
45.6
» CDXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CDXS Guru Trades in Q2 2014

Jim Simons 209,000 sh (+6.47%)
» More
Q3 2014

CDXS Guru Trades in Q3 2014

Jim Simons 281,800 sh (+34.83%)
» More
Q4 2014

CDXS Guru Trades in Q4 2014

Jim Simons 316,900 sh (+12.46%)
» More
Q1 2015

CDXS Guru Trades in Q1 2015

Jim Simons 461,900 sh (+45.76%)
» More
» Details

Insider Trades

Latest Guru Trades with CDXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.29
CDXS's P/B is ranked lower than
67% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. CDXS: 7.29 )
Ranked among companies with meaningful P/B only.
CDXS' s 10-Year P/B Range
Min: 0.83  Med: 1.88 Max: 9.41
Current: 7.29
0.83
9.41
P/S 4.31
CDXS's P/S is ranked higher than
79% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. CDXS: 4.31 )
Ranked among companies with meaningful P/S only.
CDXS' s 10-Year P/S Range
Min: 0.27  Med: 1.61 Max: 5.58
Current: 4.31
0.27
5.58
Current Ratio 2.33
CDXS's Current Ratio is ranked lower than
71% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CDXS: 2.33 )
Ranked among companies with meaningful Current Ratio only.
CDXS' s 10-Year Current Ratio Range
Min: 1.14  Med: 2.62 Max: 3.98
Current: 2.33
1.14
3.98
Quick Ratio 2.24
CDXS's Quick Ratio is ranked lower than
68% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CDXS: 2.24 )
Ranked among companies with meaningful Quick Ratio only.
CDXS' s 10-Year Quick Ratio Range
Min: 1.07  Med: 2.46 Max: 3.75
Current: 2.24
1.07
3.75
Days Inventory 70.30
CDXS's Days Inventory is ranked higher than
67% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. CDXS: 70.30 )
Ranked among companies with meaningful Days Inventory only.
CDXS' s 10-Year Days Inventory Range
Min: 31.91  Med: 45.73 Max: 64.46
Current: 70.3
31.91
64.46
Days Sales Outstanding 33.50
CDXS's Days Sales Outstanding is ranked higher than
76% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. CDXS: 33.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDXS' s 10-Year Days Sales Outstanding Range
Min: 31.19  Med: 52.25 Max: 92.67
Current: 33.5
31.19
92.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 65.67
CDXS's Price/Net Cash is ranked lower than
92% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. CDXS: 65.67 )
Ranked among companies with meaningful Price/Net Cash only.
CDXS' s 10-Year Price/Net Cash Range
Min: 3.45  Med: 9.18 Max: 76
Current: 65.67
3.45
76
Price/Net Current Asset Value 19.70
CDXS's Price/Net Current Asset Value is ranked lower than
79% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. CDXS: 19.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CDXS' s 10-Year Price/Net Current Asset Value Range
Min: 2.19  Med: 4.19 Max: 22.8
Current: 19.7
2.19
22.8
Price/Tangible Book 11.94
CDXS's Price/Tangible Book is ranked lower than
75% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CDXS: 11.94 )
Ranked among companies with meaningful Price/Tangible Book only.
CDXS' s 10-Year Price/Tangible Book Range
Min: 1.34  Med: 2.64 Max: 13.82
Current: 11.94
1.34
13.82
Price/Median PS Value 2.68
CDXS's Price/Median PS Value is ranked lower than
83% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. CDXS: 2.68 )
Ranked among companies with meaningful Price/Median PS Value only.
CDXS' s 10-Year Price/Median PS Value Range
Min: 0.2  Med: 0.97 Max: 3.1
Current: 2.68
0.2
3.1
Earnings Yield (Greenblatt) (%) -13.49
CDXS's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CDXS: -13.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CDXS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -26.2  Med: 0.00 Max: 0
Current: -13.49
-26.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4QK.Germany,
Codexis Inc was incorporated in Delaware in January 2002. The Company is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. Its proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing. The Company has commercialized its technology and products in the pharmaceuticals market. The pharmaceutical customers, which include several pharmaceutical companies, use its technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. It has recently started to use its technology to develop biocatalysts for use in the fine chemicals markets. The fine chemicals market is similar to its pharmaceutical business and consists of several large market segments, including food, animal feed, polymers, flavors and fragrances and agricultural chemicals, and so it is a natural fit for its technology. Its technology is also currently being used by a customer to manufacture butadiene, an intermediate for the manufacture of polymers. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (API), and Codex Biocatalyst Kits and Panels. It markets and sells enzymes, development services and Codex Biocatalyst Kits and Panels screening tools that enable novel manufacturing processes for APIs and their precursor pharmaceutical intermediates. It also markets and sells pharmaceutical intermediates that are manufactured using its custom enzymes. The registered and pending United States and foreign trademarks include Codexis, Codex, CodeEvolver, CodeXporter, CodeXol, CodeXyme, Powered by CodeEvolver, We Are Biocatalysis, Mosaic, Sage, Microcyp, Hit from a Kit, Prosar and a Codexis and design mark. The competitors include Solvias Inc. and Takasago International Corporation who use metal-based chemical reactions for their pharmaceutical products, industrial enzyme companies, such as Novozymes, as well as subsidiaries of larger pharmaceutical companies, such as DSM, Cambrex Corporation and Almac Group Ltd. There is also competition in the customized and optimized enzyme area from several small European companies, such as BRAIN AG, C-LEcta GmbH and evocatal GmbH. The Company's operations comply with environmental laws and regulations.
» More Articles for CDXS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Lows Highlight: SEAS, AMTG, AHH, NCTY, CDXS Dec 30 2013 
comment on CDXS Mar 23 2013 
Weekly CEO Buys Highlight: AKAM, DRC, MDRX, MTG, CDXS Mar 17 2013 
A New Beginning for Codexis? Mar 08 2013 
Weekly CFO Buys Highlight: ASNB, FXCM, CDXS, VTNC, BRS Sep 24 2012 

More From Other Websites
CODEXIS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 10 2015
CODEXIS INC Financials May 15 2015
10-Q for Codexis, Inc. May 09 2015
Codexis reports 1Q loss May 07 2015
Codexis reports 1Q loss May 07 2015
Codexis Reports Financial Results for the First Quarter of 2015 May 07 2015
Codexis Inc Earnings Call scheduled for 4:30 pm ET today May 07 2015
CODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2015
Codexis Reports Financial Results for the First Quarter of 2015 May 07 2015
Q1 2015 Codexis Inc Earnings Release - After Market Close May 07 2015
Codexis to Present at May Investor Conferences May 05 2015
Codexis to Present at May Investor Conferences May 05 2015
Codexis to Hold 2015 First Quarter Conference Call on May 7 Apr 30 2015
Codexis to Hold 2015 First Quarter Conference Call on May 7 Apr 30 2015
Can Avery Dennison (AVY) Keep the Earnings Streak Alive? - Analyst Blog Apr 28 2015
Will Eaton (ETN) Q1 Earnings Miss Estimates on Seasonality? - Analyst Blog Apr 27 2015
Will Owens-Illinois (OI) Miss Q1 Earnings on Currency Woes? - Analyst Blog Apr 27 2015
Grainger (GWW) to Grow on Sales Initiatives, Risks Linger - Analyst Blog Apr 21 2015
Will Caterpillar (CAT) Beat Earnings Estimates in Q1? - Analyst Blog Apr 21 2015
Precision Unveils Q4 Asset Charges & Restructuring Actions - Analyst Blog Apr 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK